Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Date:2/4/2009

-Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles-

TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the primary efficacy endpoint in the first stage of its ongoing Phase II clinical trial in patients with non-small cell lung cancer (NSCLC). The open-label, Simon two-stage study is designed to evaluate the safety and efficacy of the combination of bavituximab with the chemotherapy drugs carboplatin and paclitaxel in NSCLC patients. Seventeen of the 21 patients enrolled in Stage A were deemed evaluable for tumor response by the end of four treatment cycles, with six patients achieving partial tumor responses and one patient achieving a complete tumor response, according to RECIST criteria. These preliminary results exceed the pre-specified benchmark criteria established for enrolling an additional 28 patients in Stage B of this trial, up to a total of 49 patients.

"We are very pleased with the promising early results from this pilot Phase II lung cancer trial and will now move forward to initiate the second stage of the study," said Steven W. King, president and CEO of Peregrine. "We are encouraged by the number of tumor responses seen at this early time point of approximately 12 weeks in patients with NSCLC, a leading cause of cancer deaths that responds poorly to current treatments. As these patients continue on treatment, we will be assessing them for further signs of anti-tumor activity, and we look forward to sharing more data from this study as patient treatment and follow-up progress."

The primary objective of the multi-center Phase II clinical trial in patients with previously untreated locally advanced or metastatic NS
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
3. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
4. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
7. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
8. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
10. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
11. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... developed a new microscopy technology that allows them ... higher-than-ever resolution. , Dubbed "Complementation Activated Light Microscopy" ... are an order of magnitude finer than conventional ... of biomolecules at the nanometer scale. , In ... Nature Communications , the researchers behind CALM used ...
(Date:9/18/2014)... memory device for computing may have just taken an ... New York led by chemist Stephen O,Brien have discovered ... properties. , Combining both properties is very exciting scientifically ... for the devices that might ultimately be designed, in ... a single material, however, has proved difficult until now. ...
(Date:9/18/2014)... San Diego, CA (PRWEB) September 18, 2014 ... promotions which include Sartorius/Biohit, Socorex, Capp, and ... working with volumes of 100 uL or less ... pharmaceutical, oncology, and forensic applications. , The ... of high quality and economic alternative products to ...
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 Whitehouse ... negotiations with Salem Realty Group and has acquired an ... space within the Salem Executive Complex adjacent to its ... was held on Friday September 5th. Whitehouse Labs is ... the entire space specifically for package testing. The prime ...
Breaking Biology Technology:Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Oxides discovered by CCNY team could advance memory devices 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4
... - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - ... the fiscal 2009 third quarter and nine-month period ended ... for its fiscal year 2009 now ending on February, ... period ended February 28, 2009 in the range of ...
... regular improvements in information technology, says Slava Rotkin, but ... Take the laptop, for example. Its components, especially its ... while the instrument,s power and capacity increase. But heat ... melt and the laptop hardware to fail. , Indeed, ...
... Approval for SIMPONI , ... Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: ... granted approval of SIMPONI (TM) (golimumab),as a once-monthly, ... active rheumatoid arthritis (RA), active psoriatic arthritis (PsA),and ...
Cached Biology Technology:Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5New 'near-field' radiation therapy promises relief for overheating laptops 2New 'near-field' radiation therapy promises relief for overheating laptops 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8
(Date:9/17/2014)... as an EC-FP5 four-year project, delivering its first release ... successful participations in several EC projects, as a part ... project (EU BON), to increase the general awareness of ... the general dissemination of the Fauna Europaea results, the ... its novel e-Publishing tools to prepare data papers for ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... the human retinoblastoma protein gene are a leading cause ... turned to fruit fly eyes to unlock the secrets ... paper featured on the cover of the current issue ... State University researchers provide the first detailed examination of ... the human cancer gene, said Irina Pushel, MSU undergraduate ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2
... and consume a wide range of prey, which sometimes includes ... why females eat males before or after mating. Researchers Shawn ... in a study published in the September issue of the ... than previously thought. Males are more likely to be eaten ...
... 2008)A set of stripy legs in a camera trap photo ... say researchers from the Wildlife Conservation Society. The legs belong ... the Democratic Republic of Congo,s Virunga National Park, despite over ... "This is the first time this species has been captured ...
... Ore. Contrary to 40 years of conventional wisdom, a ... Nature suggests that old growth forests are usually "carbon ... the atmosphere and mitigate climate change for centuries. However, ... by international treaties and have been considered of no significance ...
Cached Biology News:In spiders, size matters: Small males are more often meals 2Photo reveals rare okapi survived poaching onslaught 2Old growth forests are valuable carbon sinks 2Old growth forests are valuable carbon sinks 3
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Request Info...
LabFax: Immunochemistry...
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Biology Products: